Omnicell (OMCL) Stock Price, News & Analysis

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" OMCL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OMCL, but not buy additional shares or sell existing shares.
View OMCL analyst ratings or view top-rated stocks.

6 analysts have issued 12-month target prices for Omnicell's shares. Their OMCL share price targets range from $26.00 to $75.00. On average, they expect the company's share price to reach $42.20 in the next twelve months. This suggests a possible upside of 51.6% from the stock's current price.
View analysts price targets for OMCL or view top-rated stocks among Wall Street analysts.

Omnicell's stock was trading at $37.63 at the start of the year. Since then, OMCL shares have decreased by 26.0% and is now trading at $27.83.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our OMCL earnings forecast.

Omnicell will be holding an earnings conference call on Thursday, May 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

Omnicell, Inc. (NASDAQ:OMCL) issued its quarterly earnings results on Thursday, February, 8th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.22. The firm had revenue of $258.85 million for the quarter, compared to the consensus estimate of $256 million. Omnicell had a negative net margin of 1.78% and a positive trailing twelve-month return on equity of 3.43%.

ETFs with the largest weight of Omnicell (NASDAQ:OMCL) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), ROBO Global Robotics & Automation ETF (ROBO), SPDR S&P Health Care Equipment ETF (XHE), ROBO Global Healthcare Technology and Innovation ETF (HTEC), Invesco S&P SmallCap Health Care ETF (PSCH), Global X Robotics & Artificial Intelligence Thematic ETF (BOTZ) and Invesco Nasdaq Future Gen 200 ETF (QQQS).iShares U.S. Medical Devices ETF (IHI).

Omnicell updated its first quarter 2024 earnings guidance on Thursday, February, 8th. The company provided EPS guidance of -0.100--0.100 for the period, compared to the consensus EPS estimate of 0.310. The company issued revenue guidance of $232.0 million-$242.0 million, compared to the consensus revenue estimate of $262.4 million.

150 employees have rated Omnicell Chief Executive Officer Randall A. Lipps on Glassdoor.com. Randall A. Lipps has an approval rating of 68% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Adobe (ADBE), Micron Technology (MU), NVIDIA (NVDA), Applied Materials (AMAT), Alibaba Group (BABA) and Intel (INTC).

Omnicell's stock is owned by a variety of retail and institutional investors. Top institutional investors include Tributary Capital Management LLC (0.69%), Diversified Trust Co (0.03%) and Counterpoint Mutual Funds LLC (0.02%). Insiders that own company stock include Christine Marie Mellon, Dan S Johnston, James T Judson, Joanne B Bauer, Joseph Brian Spears, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann.
View institutional ownership trends.

Shares of OMCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.